Clinical Trial

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-01
notable Trial sites expanded: 0 -> 48 locations 2026-05-01
Trial Details
NCT Number NCT07428499
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
Enrollment 90 participants
Start Date 2026-04-02
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-16